Condition

Chronic Obstructive Pulmonary Disease Moderate

ClinicalTrials.gov condition label

Clinical trials12

Recruiting1

Common interventions18

Lead sponsors shown12

Clinical trials

12 shown

Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary DiseaseNCT06072690 · 2021-04-15

Chest Mobility Exercises Versus Proprioceptive Neuromuscular Facilitation in Patients With COPDNCT06269029 · 2024-02-17

Effect of NMES on Quadriceps Muscle Strength and Endurance in Patients With COPDNCT05539547 · 2022-10-01

Manual Therapy in Addition to Pulmonary Rehabilitation in Moderate Chronic Obstructive Pulmonary Disease.NCT04386590 · 2022-06-15

Observational Study of the Wellinks Solution Impact on Quality of Life and Clinical Outcomes in Patients With COPDNCT05259280 · 2022-01-05

Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary DiseaseNCT04206007 · 2020-06-11

Association of Cathelicidin and Vitamin D Levels With the Category and Course of COPDNCT05431218 · 2020-02-18

Aerosol Therapy in Obese COPD Patients.NCT03031093 · 2017-12-02

The Effects of RPL554 in Addition to Tiotropium in COPD PatientsNCT03028142 · 2017-01-01

Effect Of Ketamine Infusion In Patients With COPD Applied One Lung VentilationNCT02962999 · 2017-01-01

Beetroot Juice - Effects on Performance in Chronic Obstructive Pulmonary Disease PatientsNCT03020862 · 2013-12-01

The Study of CCTM and Common DiseasesNCT02998944 · 2011-01-01

Common interventions

1.5 mg RPL554 plus tiotropiumDRUG1 6 mg RPL554 plus tiotropiumDRUG1 Chest mobility exercisesOTHER1 Cholecalciferol LiquidDRUG1 Dietary beetroot juiceDIETARY_SUPPLEMENT1 High Flow Nasal CannulaDEVICE1 inhalation protocolRADIATION1 KetamineDRUG1 Manual Therapy Plus Pulmonary RehabilitationOTHER1 Neuromuscular Electrical Nerve StimulationDEVICE1 Placebo plus tiotropiumDRUG1 proprioceptive neuromuscular facilitationOTHER1 SalineDRUG1 Sham InterventionOTHER1 UMC119-06BIOLOGICAL1 UNKNOWNOTHER1 Usual Physiotherapy treatment (Chest Physiotherapy and mobility)OTHER1 WellinksOTHER1

Leading sponsors

Cairo University1 Canandaigua VA Medical Center1 Convexity Scientific Inc1 Cukurova University1 Karaganda Medical University1 Lithuanian University of Health Sciences1 Meridigen Biotech Co., Ltd.1 Randall Debattista1 Shanghai Tongji Hospital, Tongji University School of Medicine1 Universidade Federal do Rio Grande do Norte1 University of Aarhus1 Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA1

Trial status mix

COMPLETED8

UNKNOWN3

RECRUITING1

Phase mix

NA4

PHASE22

PHASE42

EARLY_PHASE11

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.